SG171583A1 - Composition for the treatment of resistant cancers comprising oridonin - Google Patents
Composition for the treatment of resistant cancers comprising oridoninInfo
- Publication number
- SG171583A1 SG171583A1 SG201102764-6A SG2011027646A SG171583A1 SG 171583 A1 SG171583 A1 SG 171583A1 SG 2011027646 A SG2011027646 A SG 2011027646A SG 171583 A1 SG171583 A1 SG 171583A1
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- oridonin
- resistant
- composition
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- SDHTXBWLVGWJFT-XKCURVIJSA-N oridonin Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12[C@@H](O)CCC(C)(C)[C@H]1[C@H](O)[C@@]3(O)OC2 SDHTXBWLVGWJFT-XKCURVIJSA-N 0.000 title abstract 2
- CAQAFLRZJHXSIS-UHFFFAOYSA-N oridonin Natural products CC1(C)C=CC(O)C23COC(O)(C(O)C12)C45C(O)C(CCC34)C(=C)C5=O CAQAFLRZJHXSIS-UHFFFAOYSA-N 0.000 title abstract 2
- 208000016691 refractory malignant neoplasm Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010008342 Cervix carcinoma Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 206010038111 Recurrent cancer Diseases 0.000 abstract 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000010881 cervical cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0609386.8A GB0609386D0 (en) | 2006-05-11 | 2006-05-11 | Treating drug resistant cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG171583A1 true SG171583A1 (en) | 2011-06-29 |
Family
ID=36637342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG201102764-6A SG171583A1 (en) | 2006-05-11 | 2007-05-10 | Composition for the treatment of resistant cancers comprising oridonin |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9089546B2 (zh) |
| EP (1) | EP2026780A1 (zh) |
| JP (1) | JP2009536635A (zh) |
| KR (1) | KR20090037395A (zh) |
| CN (1) | CN101495108B (zh) |
| AU (1) | AU2007251374A1 (zh) |
| BR (1) | BRPI0712788A2 (zh) |
| CA (1) | CA2651795A1 (zh) |
| GB (1) | GB0609386D0 (zh) |
| IL (1) | IL195039A0 (zh) |
| MX (1) | MX2008014395A (zh) |
| NO (1) | NO20085147L (zh) |
| RU (1) | RU2455002C2 (zh) |
| SG (1) | SG171583A1 (zh) |
| WO (1) | WO2007132190A1 (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1994293A (zh) * | 2006-08-18 | 2007-07-11 | 上海交通大学医学院附属瑞金医院 | 冬凌草甲素在制药中的应用 |
| FR2944435B1 (fr) | 2009-04-17 | 2011-05-27 | Sederma Sa | Composition cosmetique comprenant de l'oridonine |
| WO2013049507A1 (en) | 2011-09-30 | 2013-04-04 | Perio Sciences, Llc | Antioxidant compositions for treatment of inflammation or oxidative damage |
| CN102648956A (zh) * | 2012-05-18 | 2012-08-29 | 漳州市中草药研究所 | 一种治疗乳腺癌的中草药制剂及其制备方法 |
| WO2014047780A1 (zh) * | 2012-09-25 | 2014-04-03 | 鼎泓国际投资（香港）有限公司 | 含有芹菜素及芹菜素类衍生物和冬凌草甲素及冬凌草甲素类衍生物的药物组合物及其应用 |
| CN104434939B (zh) * | 2014-11-14 | 2017-05-03 | 深圳大学 | 三七皂苷r7和冬凌草甲素减毒增效抗肿瘤药物组合物及其应用 |
| US11185527B2 (en) | 2017-06-26 | 2021-11-30 | Wayne State University | Methods and compositions relating to steroid hormone receptor-dependent cancers |
| KR101948247B1 (ko) * | 2017-07-14 | 2019-02-14 | 한국생명공학연구원 | Oct4 저해용 조성물 및 이의 용도 |
| MX2021005764A (es) * | 2018-11-16 | 2021-10-01 | Jiangsu Hengrui Medicine Co | Composición farmacéutica que comprende inhibidores de poli (adenosina difosfato (adp)-ribosa) polimerasas (parp). |
| KR102263396B1 (ko) * | 2019-11-01 | 2021-06-10 | 가톨릭관동대학교산학협력단 | 이소리퀴리티제닌 유도체를 포함하는 골 질환의 예방 또는 치료용 약학적 조성물 |
| CN111467367B (zh) * | 2020-05-22 | 2021-08-17 | 陈炯 | 一种用于抑制肿瘤细胞生长的植物单体组合物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1476016A (en) * | 1975-07-31 | 1977-06-10 | Nippon Shinyako Co Ltd | Pharmaceutical compositions having anti-tumour activity |
| IT1271301B (it) * | 1994-12-20 | 1997-05-27 | Indena Spa | Calconi naturali e sintetici e loro esteri ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno e formulazioni che li contengono |
| US20030035851A1 (en) * | 2001-02-08 | 2003-02-20 | Sophie Chen | Anti-cancer agents and method of use thereof |
| US20050032882A1 (en) * | 2002-03-06 | 2005-02-10 | Sophie Chen | Botanical extract compositions and methods of use |
| CN1220519C (zh) * | 2002-08-26 | 2005-09-28 | 上海中耀生物科技有限公司 | 治疗前列腺癌的中药组合物及其制备方法和制药应用 |
| WO2004080474A1 (en) * | 2003-03-06 | 2004-09-23 | The Medical Research And Education Trust | Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising prenyl flavonoids |
-
2006
- 2006-05-11 GB GBGB0609386.8A patent/GB0609386D0/en not_active Ceased
-
2007
- 2007-05-10 CN CN200780017079.7A patent/CN101495108B/zh not_active Expired - Fee Related
- 2007-05-10 RU RU2008148833/15A patent/RU2455002C2/ru not_active IP Right Cessation
- 2007-05-10 MX MX2008014395A patent/MX2008014395A/es unknown
- 2007-05-10 AU AU2007251374A patent/AU2007251374A1/en not_active Abandoned
- 2007-05-10 WO PCT/GB2007/001720 patent/WO2007132190A1/en active Application Filing
- 2007-05-10 SG SG201102764-6A patent/SG171583A1/en unknown
- 2007-05-10 US US12/300,350 patent/US9089546B2/en not_active Expired - Fee Related
- 2007-05-10 CA CA002651795A patent/CA2651795A1/en not_active Abandoned
- 2007-05-10 BR BRPI0712788-0A patent/BRPI0712788A2/pt not_active IP Right Cessation
- 2007-05-10 EP EP07732746A patent/EP2026780A1/en not_active Withdrawn
- 2007-05-10 JP JP2009508491A patent/JP2009536635A/ja active Pending
- 2007-05-10 KR KR1020087030274A patent/KR20090037395A/ko not_active Application Discontinuation
-
2008
- 2008-11-02 IL IL195039A patent/IL195039A0/en unknown
- 2008-12-10 NO NO20085147A patent/NO20085147L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090037395A (ko) | 2009-04-15 |
| EP2026780A1 (en) | 2009-02-25 |
| CA2651795A1 (en) | 2007-11-22 |
| CN101495108B (zh) | 2014-10-15 |
| AU2007251374A1 (en) | 2007-11-22 |
| BRPI0712788A2 (pt) | 2012-09-11 |
| WO2007132190A1 (en) | 2007-11-22 |
| NO20085147L (no) | 2009-02-09 |
| US9089546B2 (en) | 2015-07-28 |
| RU2008148833A (ru) | 2010-06-20 |
| JP2009536635A (ja) | 2009-10-15 |
| RU2455002C2 (ru) | 2012-07-10 |
| US20100016420A1 (en) | 2010-01-21 |
| MX2008014395A (es) | 2009-04-23 |
| GB0609386D0 (en) | 2006-06-21 |
| CN101495108A (zh) | 2009-07-29 |
| IL195039A0 (en) | 2009-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG171583A1 (en) | Composition for the treatment of resistant cancers comprising oridonin | |
| IL258880A (en) | Compounds of diarylhydantoin | |
| HK1124040A1 (en) | Heteroalkyl linked pyrimidine derivatives | |
| MX368173B (es) | Una composición farmacéutica que comprende una proteína de fusión actriia-fc expresada de células cho. | |
| HK1109638A1 (en) | Dr5 antibodies and uses thereof dr5 | |
| MX2009006466A (es) | Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina. | |
| UA100852C2 (ru) | Композиции для лечения рака | |
| SG164368A1 (en) | Treatment of cancer | |
| MY146112A (en) | Long-term feed - cancer patient | |
| MX2007016322A (es) | Composiciones y metodos para el diagnostico y tratamiento de tumor. | |
| WO2006113483A3 (en) | Methods and compositions for treating or preventing cancer | |
| UA91848C2 (ru) | Применение соединений диосметина в лечении и предотвращении тромботическим патологиям | |
| WO2011041336A3 (en) | Treating notch1-antagonist-resistant cancer (s) using notch3 antagonists | |
| TN2009000194A1 (en) | Novel antiproliferation antibodies | |
| NZ579478A (en) | Epha3 antibodies for the treatment of solid tumors | |
| WO2008060945A3 (en) | Diagnosis and treatment of breast cancer | |
| MX2009011822A (es) | Hidroxi sulfonatos de compuestos de quinonicos y sus usos. | |
| MX2009004436A (es) | Derivados de quinazolina macrociclicos como inhibidores del factor de crecimiento endotelial vascular r3. | |
| EP1904088A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| EP2124554A4 (en) | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | |
| WO2007047803A3 (en) | Use of prolactin in the prophylactic treatment of cancer | |
| WO2011031833A3 (en) | Human anti-cancer antibodies | |
| IL191690A0 (en) | Therapy of malignant neoplasias | |
| WO2007139778A3 (en) | Rhamnose substituents of sl0101 and therapeutic uses thereof | |
| TW200640948A (en) | DR5 antibodies and uses thereof |